Outside prostate biopsies exhibit 2.1- to 2.8-fold higher AS misclassification rates compared to institutional biopsies, supporting systematic second-opinion review and careful confirmation before AS enrollment and eliminating upgrade risk.
Hyean Jun Park, Jong Ho Park, Younsoo Chung et al.· Investigative and Clinical U...· 1 citation
In this large multicenter study, PSAD was the strongest predictor of transition to AT during AS for PCa, and beyond disease-related factors, patient condition appeared to influence real-world decisions about continuing AS.
Joongwon Choi, Chung-Un Lee, S. Jeon et al.· Investigative and Clinical U...· 0 citations
Machine learning–based ctDNA methylation profiling identifies a clinically actionable molecular signature associated with rare dual-resistance phenotypes in advanced prostate cancer, which suggests a rare epithelial-fixed, AR-reinforced phenotype that evades conventional therapeutic pressure through epigenetic stabiliz...
Jae-Seung Chung, Hyungseok Cho, Da-Won Kim et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.